Carotid artery atherosclerotic plaque characteristics associated with a plaque progression and a risk of stroke
Project goals
Atherosclerosis is the most common cause of stroke. The aims of the project are to compare the visual and digital analysis of ultrasonographic and MRI images of atherosclerotic plaque in carotids in vivo and in vitro with the histological composition of the plaque obtained from patients indicated for carotid endarterectomy, to compare the characteristics of symptomatic and asymptomatic plaques, subsequently to verify a hypothesis that ultrasound can identify the sonographic plaque characteristics associated with an increased risk of plaque progression and stroke onset patients with carotic atherosclerosis. Ti identify the value of MRI in this indication. Identification of the characteristics of "unstable" atherosclerotic plaque will allow to improve the indication criteria for carotid endarterectomy or stenting and also for a potential change of a medical therapy in patients with "unstable" atherosclerotic plaque in the future. The diagnostic tools could enable to improve diagnosis of “unstable“ plaque in carotids using this new plaque characteristics evaluation.
Keywords
aterosklerotický plátatherosclerotic plaquesonografiestenóza karotidycharakteristika plátusonographycarotid stenosiscévní mozková příhodaplaque charactericsstroke
Public support
Provider
Ministry of Health
Programme
Programme to support medical applied research in 2015 to 2022
Call for proposals
Zdravotnický AV 3 (SMZ0201701)
Main participants
Ústřední vojenská nemocnice - Vojenská fakultní nemocnice Praha
Contest type
VS - Public tender
Contract ID
17-31016A
Alternative language
Project name in Czech
Morfologické charakteristiky aterosklerotického plátu v karotické tepně spojené s progresí plátu a rizikem cévní mozkové příhody
Annotation in Czech
Ateroskleróza je nejčastější příčinou cévní mozkové příhody (CMP). Cílem projektu je srovnání vizuální a digitální analýzy ultrazvukového obrazu karotického aterosklerotického plátu in vivo a in vitro s histologickým složením plátu získaného od pacientů indikovaných ke karotické endarterektomii, srovnání charakteristik symptomatických a asymptomatických plátů a ověření, zda lze identifikovat charakteristiky ultrazvukem zobrazeného plátu spojené se zvýšeným rizikem jeho progrese a vzniku ischemické CMP (tzv. “nestabilní” plát). Identifikace ultrazvukové charakteristiky „nestabilního“ aterosklerotického plátu umožní v budoucnosti zlepšit indikační kritéria pro karotickou endarterektomii, stenting a event. změnu farmakoterapie u pacientů s „nestabilním“ aterosklerotickým plátem. Pro finanční nenáročnost a dostupnost sonografických přístrojů lze předpokládat, že by tuto možnost zlepšení diagnostiky rizikovosti aterosklerotického plátu bylo možno využít u většiny pacientů s aterosklerotickým plátem v karotidách. Dále bude provedena analýza MRI obrazu plátu a histologických nálezů.
Scientific branches
R&D category
AP - Applied research
CEP classification - main branch
EI - Biotechnology and bionics
CEP - secondary branch
—
CEP - another secondary branch
—
20801 - Environmental biotechnology
20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management
20803 - Environmental biotechnology related ethics
20901 - Industrial biotechnology
20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation
20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials
30401 - Health-related biotechnology
30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)
30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])
30404 - Biomaterials (as related to medical implants, devices, sensors)
30405 - Medical biotechnology related ethics
40401 - Agricultural biotechnology and food biotechnology
40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming
40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
The aim of the project was to identify unstable atherosclerotic plaque in the carotid artery with the risk of progression and stroke during duplex ultrasound examination by visual and digital analysis of plaque images in vivo, in vitro and histological findings. Next, compare MRI findings with histological findings. The project was realized in accordance with the methodology, the recruitment of patients was observed, in addition, more patients were examined than planned. The solution of the project brought new findings that could be useful in the clinical management of patients. As part of the solution of the partial goals of the project, a large set of data was obtained with the potential for further analysis or obtaining objective results. As for the main outputs (publications) of the project at the time of the evaluation, it unfortunately did not achieve the pre-set objectives. The summary IF of all publications is not given in the final report. Compared to the expected number, fewe
Solution timeline
Realization period - beginning
Apr 1, 2017
Realization period - end
Dec 31, 2020
Project status
U - Finished project
Latest support payment
Jun 28, 2018
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP21-MZ0-NV-U/03:1
Data delivery date
Jun 25, 2021
Finance
Total approved costs
15,272 thou. CZK
Public financial support
14,419 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
852 thou. CZK
Basic information
Recognised costs
15 272 CZK thou.
Public support
14 419 CZK thou.
94%
Provider
Ministry of Health
CEP
EI - Biotechnology and bionics
Solution period
01. 04. 2017 - 31. 12. 2020